ARS Pharmaceuticals, Inc. SPRY Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $84.28M-5.5% | $89.15M+297,063% | $30K-97.7% | $1.32M-76.1% | ||
| $13.18M-32.7% | $19.58M-3.4% | $20.27M+10.3% | $18.38M— | ||
| $230.12M+221% | $71.68M— | —— | —— | ||
| $263.73M+186% | $92.23M+36.5% | $67.55M+83.4% | $36.83M— | ||
| -$179.45M— | —— | -$67.52M-90.1% | -$35.52M— | ||
| -212.9%— | —— | -225,066.7%-222,368pp | -2,698.8%— | ||
| $8.07M-29.0% | $11.37M-13.6% | $13.16M+1,477% | $834K+206% | ||
| -$171.38M-2,168% | $8.29M+115% | -$54.37M— | —— | ||
| -$80K-128% | $288K— | $0— | —— | ||
| -$171.3M-2,242% | $8M+115% | -$54.37M-56.8% | -$34.68M— | ||
| -203.3%-212pp | 9%+181,226pp | -181,216.7%-178,581pp | -2,635.4%— | ||
| -$1.75-2,600% | $0.07+112% | -$0.57+34.5% | -$0.87— | ||
| -$178.08M-270% | -$48.13M+28.6% | -$67.45M-92.3% | -$35.07M— | ||
| -211.3%-157pp | -54%+224,769pp | -224,823.3%-222,158pp | -2,664.9%— | ||
| -$179.45M-272% | -$48.21M+28.6% | -$67.52M-90.1% | -$35.52M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is ARS Pharmaceuticals, Inc.'s revenue?
- ARS Pharmaceuticals, Inc. (SPRY) generated $99.0M in revenue over the trailing twelve months, up 1.9% year over year.
- Is ARS Pharmaceuticals, Inc. profitable?
- ARS Pharmaceuticals, Inc. is not currently profitable: it reported a net loss of $198.0M over the trailing twelve months, a -200.0% net margin.
- What is ARS Pharmaceuticals, Inc.'s earnings per share?
- ARS Pharmaceuticals, Inc.'s diluted EPS over the trailing twelve months is $-2.01.
- Where does ARS Pharmaceuticals, Inc.'s income statement data come from?
- Every line is extracted from ARS Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
